After decades with no FDA-approved therapy, Amgen and Novartis both have Phase 3 winners in Sjögren's disease. The harder question is whether either can beat the symptom patients feel most: dryness.
Top stories
Newsletter
Pipeline, markets, policy, and science. Once a week.
A reported offer for the established MC4R franchise and fresh funding for Lilly-backed Superluminal point to growing interest in the brain’s hunger pathway. Palatin is engineering several ways to compete in its next generation.
Evommune is licensing a VAV1 molecular glue degrader from China's Hinova to chase JAK-like efficacy in rheumatoid arthritis without the class's boxed safety warnings.
Agios won a decisive hemoglobin response in sickle cell but missed the pain-crisis endpoint. A liver-safety question has now pushed the mitapivat decision to February.
In depth
A sign-and-close reverse merger leaves Bolt's original stockholders with 6.9% of the company as Prana's IL-4Rα/TSLP bispecific inherits the Nasdaq listing, backed by a $120 million placement closing today.
Read the storyLilly's Jaypirca just won frontline CLL with a large survival edge, but only over chemoimmunotherapy the field is retiring. Lilly itself says the drug belongs in second line, and that sequencing logic shapes what the new label is really worth.
Viatris is paying $1.65 billion for Pacira, roughly 2.2 times trailing revenue. The price only makes sense if you count EXPAREL's early 2030 licensed generic cliff and the four years of runway before it.
With only about 5% of rare conditions carrying an FDA-approved treatment, the agency is trying to turn case-by-case flexibility into written, predictable defaults. Whether that produces certainty or new rigidity is the open question.
A Nature paper finds that one arginine transfer RNA, tRNA1 Arg(UCU), keeps prostate tumors on androgen receptor signaling. When it falls, cells slip into a lineage-plastic, AR-inhibitor-resistant state.
